NeuroBo Pharmaceuticals, Inc. Stock News

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiom

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiom

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.39%

It was a trading shortened week with impressive gains for all major US stock indexes as stocks recorded one of their best weekly gains on record.. Is the worst for the stock market already priced in f

Movers Indices • S&P 500 ETF (NYSE:SPY) rose 1.28% to $277.51.• Nasdaq ETF (NASDAQ:QQQ) rose 0.74% to $202.05.• Dow Jones Industrial Average ETF (NYSE:DIA) rose 1.50% to $237.81.• FTSE/Xinhua

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiom

ITV will show all of England’s games again this summer, with every other match available on demand. As Rob Smyth wrote in 2007, highlights may be few and far between

The Board of Directors of Nigerian Breweries (NB) Plc has decided to pay the entire net profit of N16.01 billion recorded in 2019 to shareholders as cash dividends for the business year. Shareholde…

Dutch auctions? Reverse mergers? Direct listings? The pros and cons of IPO alternatives.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today announced that it will present at Biotech

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced me

The pending merger between Gemphire Therapeutics Inc. (GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfacti

The reasons could be a combination of higher tax rate on ‘luxury’ goods, subdued ‘animal spirits’ from stagnation/volatility/erosion in value of real estate and stock markets—the main wealth